Skip to main content
Clinical Trials/ACTRN12615001240538
ACTRN12615001240538
Completed
未知

Comparative effects of intraduodenal (ID) vs. intraileal (II) glucose on incretin hormone secretion, incretin effect, and glycaemic excursions in healthy subjects and patients with type 2 diabetes.

Royal Adelaide Hospital0 sites32 target enrollmentNovember 12, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Glucose metabolism
Sponsor
Royal Adelaide Hospital
Enrollment
32
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 12, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Type 2 diabetic subjects
  • \*Managed by diet alone (i.e. no oral hypoglycaemic drugs or insulin)
  • \*Body mass index (BMI) 20 \- 35 kg/m2
  • \*Age 18 \- 75 years
  • \*Males and post\-menopausal females (to control for the effect of the menstrual cycle on gut hormone secretion)
  • \*Glycated haemoglobin (HbA1c) greater than or equal to 6\.0% and less than or equal to 7\.9%
  • \*Haemoglobin above the lower limit of the normal range (i.e. \>135g/L for men and 115g/L for women), and ferritin above the lower limit of normal (i.e. \>10mcg/L)
  • Healthy subjects
  • \*Male and postmenopausal females aged 18 – 75 years
  • \*Body mass index (BMI) 20 \- 35 kg/m2

Exclusion Criteria

  • \*Use of any medication that may influence BP, gastrointestinal motor function, body weight or appetite (e.g. antihypertensive drugs, domperidone and cisapride, anticholinergic drugs (e.g. atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St. John's Wort etc.)
  • \*Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes on a daily basis
  • \*History of gastrointestinal disease, including significant upper or lower gastrointestinal symptoms, pancreatitis, or previous gastrointestinal surgery (other than uncomplicated appendicectomy or cholecystectomy)
  • \*Other significant illness, including epilepsy, cardiovascular or respiratory disease
  • \*Impaired renal or liver function (as assessed by calculated creatinine clearance \< 90 mL/min or abnormal liver function tests (\> 2 times upper limit of normal range))
  • \*Donation of blood within the previous 3 months
  • \*Participation in any other research studies within the previous 3 months
  • \*Females who are pre\-menopausal
  • \*Inability to give informed consent
  • \*Vegetarians

Outcomes

Primary Outcomes

Not specified

Similar Trials